2-Methyl-5-piperidin-4-yl-2,5-diaza-bicyclo[2.2.1]heptane → (S)-2-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-1-[4-(5-methyl-2,5-diaza-bicyclo[2.2.1]hept-2-yl)-piperidin-1-yl]-4-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-yl]-butan-1,4-dione
Reaction equation
[NH2:1][C:2]1[C:33]([C:34]([F:37])([F:36])[F:35])=[CH:32][C:5]([CH2:6][C@@H:7]([CH2:11][C:12](=[O:31])[N:13]2[CH2:18][CH2:17][CH:16]([N:19]3[CH2:25][CH2:24][C:23]4[CH:26]=[CH:27][CH:28]=[CH:29][C:22]=4[NH:21][C:20]3=[O:30])[CH2:15][CH2:14]2)[C:8]([OH:10])=O)=[CH:4][C:3]=1[Cl:38].[CH3:39][N:40]1[CH2:45][CH:44]2[CH2:46][CH:41]1[CH2:42][N:43]2[CH:47]1[CH2:52][CH2:51][NH:50][CH2:49][CH2:48]1>C(N(CC)CC)C>[NH2:1][C:2]1[C:33]([C:34]([F:37])([F:36])[F:35])=[CH:32][C:5]([CH2:6][C@@H:7]([CH2:11][C:12]([N:13]2[CH2:18][CH2:17][CH:16]([N:19]3[CH2:25][CH2:24][C:23]4[CH:26]=[CH:27][CH:28]=[CH:29][C:22]=4[NH:21][C:20]3=[O:30])[CH2:15][CH2:14]2)=[O:31])[C:8]([N:50]2[CH2:49][CH2:48][CH:47]([N:43]3[CH2:42][CH:41]4[CH2:46][CH:44]3[CH2:45][N:40]4[CH3:39])[CH2:52][CH2:51]2)=[O:10])=[CH:4][C:3]=1[Cl:38]Participants
4
Reactant 2
Product 1
Reagents, catalysts & solvents 1
Procedure
Prepared analogously to Example 10.26 from 100 mg (0.18 mmol) (S)-2-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-4-oxo-4-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-yl]-butanoic acid and 39.1 mg (0.2 mmol) 2-methyl-5-piperidin-4-yl-2,5-diaza-bicyclo[2.2.1]heptane using triethylamine as the base.
Sources & evidence
- ORD record
- ord-0df9ce69f7e748f1a878a9faac08e67c
- Source dataset
- uspto-grants-2009_09
- Patent number
- US07595312B2
Reaction notes
Loading…